| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (NCT05032040) | Xencor, Inc. | 2022-07-21 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483) | Exelixis | 2021-12-14 |
| A Study of NX-1607 in Adults With Advanced Malignancies (NCT05107674) | Nurix Therapeutics, Inc. | 2021-09-29 |
| Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer (NCT04862091) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-23 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04691804) | Jiangsu HengRui Medicine Co., Ltd. | 2021-03-18 |
| The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (NCT05208229) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2021-02-01 |
| PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (NCT04015622) | British Columbia Cancer Agency | 2020-10-07 |
| EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (NCT04516161) | Bayer | 2020-08-03 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors (NCT04052204) | Pfizer | 2019-12-30 |
| An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer (NCT04089553) | AstraZeneca | 2019-08-29 |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (NCT03972657) | Regeneron Pharmaceuticals | 2019-08-12 |
| 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (NCT03874884) | Peter MacCallum Cancer Centre, Australia | 2019-07-09 |
| Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (NCT03896984) | Bayer | 2019-03-18 |
| Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency (NCT03712930) | BeiGene | 2019-02-05 |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (NCT03903835) | Karolinska Institutet | 2019-02-01 |
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (NCT03811652) | MedImmune LLC | 2018-12-20 |
| Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (NCT03724747) | Bayer | 2018-12-18 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NCT03549000) | Novartis Pharmaceuticals | 2018-07-18 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (NCT03460977) | Pfizer | 2018-04-17 |
| Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT03030885) | Memorial Sloan Kettering Cancer Center | 2017-01-19 |
| Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (NCT02649790) | Karyopharm Therapeutics Inc | 2016-01-01 |
| Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide (NCT02130947) | UNC Lineberger Comprehensive Cancer Center | 2014-04-01 |
| A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (NCT01977651) | Astellas Pharma Global Development, Inc. | 2013-09-25 |
| 177Lu-PSMA-617 Managed Access Program for mCRPC Patients (NCT04825652) | Advanced Accelerator Applications | |